Cardiology

Best practices for diagnosis and management of patients with HFpEF

Podcast & Infographic

Click to listen to the podcast

Click to download the Infographic

Best practices for diagnosis and management of patients with HFpEF

E-learning Modules

Launch: 28 June 2024

Overview

Heart failure is a public health issue that affects 64 million individuals worldwide, of whom up to 55% have heart failure with preserved ejection fraction (HfpEF) (McDonagh, 2021). Hypertension is a predominant and common risk factor for HF and plays a crucial role in the development and progression of HFpEF ((McDonagh, 2021). As a result, managing blood pressure is a vital aspect of clinical care for hypertensive individuals with HFpEF. Primary care providers (PCPs) have an essential role in managing HFpEF in collaboration with specialists (Hossain, 2022). However, several studies show that diagnosing and managing HFpEF presents significant challenges for physicians, with considerable practice gaps in the clinical approach to this complex condition (Gupta, 2021). Compared with specialists, PCPs were more likely to underestimate HFpEF mortality and were less aware of sex-related differences in the prevalence of HFpEF and heart failure with reduced ejection fraction (HFrEF). In addition, fewer PCPs utilized natriuretic peptides for diagnosis, often citing cost and availability as obstacles to using these peptides. The current treatment strategy for HFpEF focuses on volume control using diuretics, and MRAs represent another class of medication that could be considered (Omote, Verbrugge, and Borlaug, 2022; Tsutsui, 2022).
Crucially, the management of comorbidities and lifestyle modifications, including weight loss and exercise, play  pivotal roles in the effective management of HFpEF (Omote, Verbrugge, and Borlaug, 2022; Tsutsui, 2022). However, challenges remain for clinicians (Sowden, 2020;  Hossain, 2022). This podcast will address the increasing prevalence of HFpEF, the growing ageing population, the rising prevalence of HFpEF risk factors and comorbidities, physicians’ limited knowledge about diagnosing and managing HFpEF, and the need to educate physicians to enable the early and accurate diagnosis and proper management of HFpEF.

Learning Objectives

After listening to this podcast, participants will be able to:

Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who manage patients with hypertension and heart failure. Some content of interest to gynaecologists, midwives, nurses involved in women’s health care.

Language

English with voice-over into Russian and Chinese

Faculty

Felix Mahfoud

Felix Mahfoud

Associate Professor
Department of Internal Medicine III
Cardiology, Angiology, Intensive Care Medicine
Saarland University Hospital
Homburg, Germany

Save the Date

Download Save the Date

· Felix Mahfoud ·

Felix Mahfoud is professor of medicine and deputy director of the Department for Internal Medicine and Cardiology at Saarland University Hospital and Visiting Professor at Harvard-MIT, Biomedical Engineering, Boston, MA. From June 1st, Felix Mahfoud will serve as Head of Department and Professor of Cardiology at University Basel, Switzerland. Professor Mahfoud holds board certifications in internal medicine, cardiology, intensive care medicine, emergency medicine, and hypertension. He is member of several editorial boards and serves as Secretary of the Council on Hypertension of the European Society of Cardiology (ESC)‚ PCR Board of Director and program committee member (topic coordinator hypertension) of the ESC congress 2023 & 2024. He has authored more than 460 articles in peer reviewed journals and was writing committee member of the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes, the 2018 ESC/ESH Guidelines for the management of arterial hypertension, and the 2023 ESH Guidelines for the management of arterial hypertension.

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.